Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 18, Issue 2, 2011, Pages 235-240

  Sho, Masayuki ^a   Tanaka, Toshihiro ^a   Yamada, Takatsugu ^a   Nomi, Takeo ^a   Akahori, Takahiro ^a   Doh, Jin ^a   Yamato, Ichiro ^a   Hokuto, Daisuke ^a   Nishiofuku, Hideyuki ^a   Marugami, Nagaaki ^a   Kanehiro, Hiromichi ^a   Kichikawa, Kimihiko ^a   Nakajima, Yoshiyuki ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Hepatic recurrence; Pancreatic cancer; Surgery

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; LEUKOPENIA; LIVER ABSCESS; LIVER METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTPATIENT CARE; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; POSTOPERATIVE CARE; POSTOPERATIVE PERIOD; PROGNOSIS; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; POSTOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79959855333     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-010-0336-7     Document Type: Article

References (28)

1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet. 2004;363:1049-57. (Pubitemid 38410779)
2. Traverso LW. Pancreatic cancer: surgery alone is not sufficient. Surg Endosc. 2006;20(Suppl 2):S446-9.
3. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247: 456-62.
4. Ferrone CR, Brennan MF, Gonen M, Coit DG, Fong Y, Chung S, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2008;12:701-6.
5. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-13. (Pubitemid 27251144)
6. Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, et al. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006;107:676-85. (Pubitemid 44232660)
7. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-77. (Pubitemid 46143304)
8. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908-15.
9. Barugola G, Falconi M, Bettini R, Boninsegna L, Casarotto A, Salvia R, et al. The determinant factors of recurrence following resection for ductal pancreatic cancer. JOP. 2007;8:132-40.
10. Hirano S, Kondo S, Hara T, Ambo Y, Tanaka E, Shichinohe T, et al. Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic body cancer: long-term results. Ann Surg. 2007;246:46-51. (Pubitemid 47012206)
11. Kosuge T, Kiuchi T, Mukai K, Kakizoe T. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol. 2006;36:159-65.
12. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21:195-200. (Pubitemid 27053441)
13. Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M, Kitano S. Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas. 2005;31:69-73. (Pubitemid 40911505)
14. Tani M, Kawai M, Miyazawa M, Hirono S, Ina S, Nishioka R, et al. Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg. 2009;394:249-53.
15. Shimada K, Sakamoto Y, Sano T, Kosuge T. The role of paraaortic lymph node involvement on early recurrence and survival after macroscopic curative resection with extended lymphadenectomy for pancreatic carcinoma. J Am Coll Surg. 2006;203: 345-52. (Pubitemid 44247756)
16. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511-8. (Pubitemid 43619152)
17. Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Tamamoto T, et al. Arterial infusion of 5-fluorouracil combined with concurrent radiotherapy for unresectable pancreatic cancer: results from a pilot study. AJR Am J Roentgenol. 2007;189: 421-8. (Pubitemid 47195929)
18. Tanaka T, Sakaguchi H, Sho M, Yamamoto K, Nishiofuku H, Nakajima Y, et al. A novel interventional radiology technique for arterial infusion chemotherapy against advanced pancreatic cancer. AJR Am J Roentgenol. 2009;192:W168-77.
19. Beger HG, Gansauge F, Buchler MW, Link KH. Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastasis. World J Surg. 1999;23:946-9. (Pubitemid 29398478)
20. Lygidakis NJ, Sgourakis G, Georgia D, Vlachos L, Raptis S. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg. 2002;236:806-13. (Pubitemid 35403236)
21. Kurosaki I, Kawachi Y, Nihei K, Tsuchiya Y, Aono T, Yokoyama N, et al. Liver perfusion chemotherapy with 5-fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study. Pancreas. 2009;38:161-7.
22. Takeda S, Inoue S, Kaneko T, Harada A, Nakao A. The role of adjuvant therapy for pancreatic cancer. Hepatogastroenterology. 2001;48:953-6. (Pubitemid 32757718)
23. Yamaue H, Tani M, Onishi H, Kinoshita H, Nakamori M, Yokoyama S, et al. Locoregional chemotherapy for patients with pancreatic cancer intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas. 2002;25: 366-72. (Pubitemid 35247215)
24. Ishikawa O, Ohigashi H, Sasaki Y, Furukawa H, Kabuto T, Kameyama M, et al. Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas. Am J Surg. 1994;168:361-4. (Pubitemid 24313215)
25. Ishikawa O, Ohigashi H, Imaoka S, Sasaki Y, Kameyama M, Nakamori S, et al. Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer. Hepatogastroenterology. 1997;44:1541-6. (Pubitemid 27526139)
26. Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, et al. Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg. 2009;250:88-95.
27. Rauchwerger DR, Firby PS, Hedley DW, Moore MJ. Equilibrative- sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res. 2000;60:6075-9.
28. Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, et al. Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. Eur J Cancer. 2003;39: 1547-51. (Pubitemid 36833220)